ASC41

ASC41 is an experimental thyromimetic prodrug metabolized in the liver by CYP3A4 to an active form, ASC41-A, that is selective for thyroid hormone receptor beta.[1] It has been studied for the treatment of non-alcoholic fatty liver disease.[2]

In 2023, Viking Therapeutics filed a lawsuit against ASC41's developer, Chinese company Ascletis BioScience, accusing it of stealing Viking's trade secrets to develop ASC41 which is allegedly similar to, or identical to, VK2809.[3][4]

In 2024, Ascletis discontinued clinical development of ASC41 following unfavorable Phase II clinical trial results.[5][6]

References

  1. ↑ Xie, Zhifu; Li, Yufeng; Cheng, Long; Huang, Yidan; Rao, Wanglin; Shi, Honglu; Li, Jingya (October 2, 2024). "Potential therapeutic strategies for MASH: from preclinical to clinical development". Life Metabolism. 3 (5) loae029. doi:10.1093/lifemeta/loae029. ISSN 2755-0230. PMC 11749562. PMID 39872142.
  2. ↑ Fröhlich, Eleonore; Wahl, Richard (4 August 2022). "Insight into Potential Interactions of Thyroid Hormones, Sex Hormones and Their Stimulating Hormones in the Development of Non-Alcoholic Fatty Liver Disease". Metabolites. 12 (8): 718. doi:10.3390/metabo12080718. ISSN 2218-1989. PMC 9414490. PMID 36005590.
  3. ↑ "Viking accuses Chinese biotech of 'ruse' to raid trade secrets and make off with NASH cache". Fierce Biotech. 3 January 2023. Retrieved 2 December 2023.
  4. ↑ "Viking Therapeutics accuses competitor of pilfering proprietary information". Chemical & Engineering News. January 9, 2023. Viking infers that ASC41 is Ascletis's version of—if not the same compound as—VK2809
  5. ↑ "Ascletis pulls FXR agonist from pipeline over phase 2 primary biliary cholangitis data". April 3, 2024.
  6. ↑ "Ascletis Announces Strategic Decisions on FXR agonist ASC42" (Press release). April 3, 2024.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.